<SEC-DOCUMENT>0001558370-18-009486.txt : 20181128
<SEC-HEADER>0001558370-18-009486.hdr.sgml : 20181128
<ACCEPTANCE-DATETIME>20181128160036
ACCESSION NUMBER:		0001558370-18-009486
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181127
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181128
DATE AS OF CHANGE:		20181128

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		181205652

	BUSINESS ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8-k.htm
<DESCRIPTION>8-K
<TEXT>
<!--HTML document created with Merrill Bridge  8.2.0.61-->
<!--Created on: 11/28/2018 2:00:23 PM-->
<html>
	<head>
		<title>
			glyc_Current Folio 8k
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;border-top:3pt double #000000 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 14pt;">
			<font style="display:inline;">UNITED STATES</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 14pt;">
			<font style="display:inline;font-weight:bold;font-size:14pt;">SECURITIES AND EXCHANGE COMMISSION</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-weight:bold;">Washington, DC 20549</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1.2pt;color:black;background-color:black;" align="center"></hr></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 14pt;">
			<font style="display:inline;font-weight:bold;font-size:14pt;">FORM 8&#8209;K</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">CURRENT REPORT</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">Pursuant to Section 13 or 15(d) of</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">The Securities Exchange Act of 1934</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">Date of Report (Date of earliest event reported): November 27, 2018</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1.2pt;color:black;background-color:black;" align="center"></hr></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 14pt;">
			<font style="display:inline;font-weight:bold;font-size:14pt;">GlycoMimetics, Inc.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">(Exact name of registrant as specified in its charter)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:29.44%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.74%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:31.78%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.54%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:29.44%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;text-decoration:underline;">Delaware</font></p>
				</td>
				<td valign="bottom" style="width:03.74%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:31.78%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;text-decoration:underline;">001-36177</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.54%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;text-decoration:underline;">06-1686563</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:29.44%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">(State or other jurisdiction of&nbsp;incorporation)</font></p>
				</td>
				<td valign="bottom" style="width:03.74%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:31.78%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">(Commission File Number)</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">(IRS Employer<br />Identification No.)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">9708 Medical Center Drive</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">Rockville, MD 20850</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">(Address of principal executive offices, including zip code)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">(240) 243-1201</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">(Registrant&#x2019;s telephone number, including area code)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">N/A</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">(Former name or former address, if changed since last report)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:5pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font>
		</p>
		<p style="margin:5pt 0pt 5pt 14.25pt;text-indent: -14.25pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">[&nbsp;&nbsp;] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font>
		</p>
		<p style="margin:5pt 0pt 5pt 14.25pt;text-indent: -14.25pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">[&nbsp;&nbsp;] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font>
		</p>
		<p style="margin:5pt 0pt 5pt 14.25pt;text-indent: -14.25pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">[&nbsp;&nbsp;] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font>
		</p>
		<p style="margin:0pt 0pt 0pt 14.25pt;text-indent: -14.25pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">[&nbsp;&nbsp;] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font>
		</p>
		<p style="margin:0pt 0pt 0pt 14.25pt;text-indent: -14.25pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Ind&#xED;cate by&nbsp;check&nbsp;mark&nbsp;whether&nbsp;the&nbsp;registrant&nbsp;is&nbsp;an&nbsp;emerging&nbsp;growth Company as defined in Rule 405 of the Securities Act of 1933 (&#xA7;230.405 of this&nbsp;chapter) &nbsp;or Rule 12b&#8209;2 of the Securities Exchange Act of 1934 (&#xA7;240.12b&#8209;2 of this&nbsp;chapter).</font>
		</p>
		<p style="margin:0pt 0pt 0pt 14.25pt;text-indent: -14.25pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Emerging&nbsp;growth&nbsp;company&nbsp;&#x2611;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">If&nbsp;an&nbsp;emerging&nbsp;growth&nbsp;company, &nbsp;indicate&nbsp;by&nbsp;check&nbsp;mark&nbsp;if&nbsp;the&nbsp;registrant has elected&nbsp;not to use the extended transition&nbsp;period&nbsp;for&nbsp;complying&nbsp;with&nbsp;any new or&nbsp;revised&nbsp;financial&nbsp;accounting&nbsp;standards&nbsp;provided&nbsp;pursuant to Section 13(a) of the Exchange Act. &nbsp;&#x2611;</font>
		</p>
		<p style="margin:0pt;border-bottom:3pt double #000000 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:5pt 0pt 12pt 45pt;text-indent: -45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Item 5.02&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;">On November 27, 2018, the Board of Directors (the &#x201C;</font><font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Board</font><font style="display:inline;font-size:10pt;">&#x201D;) of GlycoMimetics, Inc. (the &#x201C;</font><font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Company</font><font style="display:inline;font-size:10pt;">&#x201D;) increased the authorized number of members of the Board from eight to nine members and, to fill the resulting vacancy, appointed Scott T. Jackson&nbsp;to serve as a Class I director of the Company whose term will expire at the 2021 annual meeting of stockholders.&nbsp; There is no arrangement or understanding between Mr. Jackson and any other person pursuant to which he was selected as a director of the Company, and there is no family relationship between Mr. Jackson and any of the Company&#x2019;s other directors or executive officers.&nbsp;&nbsp;The Company is not aware of any transaction involving Mr. Jackson requiring disclosure under Item 404(a) of Regulation S-K. Additional information about Mr. Jackson is set forth below.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Scott Jackson</font><font style="display:inline;font-size:10pt;">, age 53, has served as a member of our Board since November 2018.&nbsp;&nbsp;Mr. Jackson served as the Chief Executive Officer and as a member of the Board of Directors of Celator Pharmaceuticals, Inc. from&nbsp;April 2008&nbsp;until&nbsp;July 2016, when the company was acquired by Jazz Pharmaceuticals plc.&nbsp;Mr. Jackson&nbsp;has more than 25 years of experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly &amp; Co., SmithKline Beecham,&nbsp;ImClone Systems Inc.,&nbsp;Centocor Inc., a division of Johnson &amp; Johnson, Eximias Pharmaceutical and&nbsp;YM BioSciences.&nbsp;He holds a B.S. in pharmacy from the&nbsp;Philadelphia College of Pharmacy&nbsp;and Science and an M.B.A. from the&nbsp;University of Notre Dame.&nbsp;Mr. Jackson presently serves on the board of directors of MacroGenics, Inc., a publicly traded pharmaceutical company, and the Board of Trustees of the Eastern Pennsylvania Chapter of&nbsp;The Leukemia&nbsp;and Lymphoma Society.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;">In accordance with the Company&#x2019;s compensation policy for non-employee directors, upon his appointment as a director, Mr. Jackson was granted a nonqualified stock option to purchase 22,000 shares of the Company&#x2019;s common stock at an exercise price of $11.52, the closing price of the Company&#x2019;s common stock on the date of grant.&nbsp;&nbsp;This option will vest and become exercisable in three equal installments on the first, second and third anniversaries of the date of grant, subject to Mr. Jackson&#x2019;s Continuous Service (as defined in the Company&#x2019;s 2013 Equity Incentive Plan) as of each vesting date.&nbsp;&nbsp;Additionally, Mr. Jackson will be entitled to receive a $40,000 annual retainer for his service as director. At each annual stockholder meeting following which Mr. Jackson&#x2019;s term as a director continues, Mr. Jackson will be entitled to receive an additional nonqualified stock option to purchase 11,000 shares of the Company&#x2019;s common stock, which option will vest and become exercisable over a one-year period following the date of grant.&nbsp;&nbsp;Mr. Jackson has also entered into the Company&#x2019;s standard form of indemnification agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Item 7.01&nbsp; Regulation FD Disclosure.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">On November 28, 2018, the Company issued a press release announcing Mr. Jackson&#x2019;s appointment to the Board.&nbsp; A copy of this press release is furnished herewith as Exhibit&nbsp;99.1 to this Current Report.</font><font style="display:inline;color:#000000;font-size:10pt;"> The information contained in the press release furnished as Exhibit 99.1 shall not be deemed &#x201C;filed&#x201D; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201C;</font><font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Exchange Act</font><font style="display:inline;color:#000000;font-size:10pt;">&#x201D;), and is not incorporated by reference into any of the Company&#x2019;s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Item 9.01 Exhibits.</font><font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">(d)&nbsp;Exhibits</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:40.00pt;padding:0pt 0.7pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.20pt;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:343.15pt;padding:0pt 0.7pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:40.00pt;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Exhibit</font></p>
				</td>
				<td valign="top" style="width:06.20pt;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:343.15pt;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:40.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Number</font></p>
				</td>
				<td valign="top" style="width:06.20pt;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:343.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Exhibit&nbsp;Description</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:40.00pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">99.1</font></p>
				</td>
				<td valign="top" style="width:06.20pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:343.15pt;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="ex-99d1.htm"><font style="display:inline;font-size:10pt;">Press Release dated November 28, 2018, &#x201C;Scott Jackson, Veteran Biopharmaceutical Executive, Joins GlycoMimetics Board of Directors.&#x201D;</font></a> &nbsp; &nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">SIGNATURES</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:37.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:58.92%;padding:0pt;">
					<p style="margin:0pt;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:41.08%;padding:0pt;">
					<p style="margin:0pt;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">GLYCOMIMETICS, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:58.92%;padding:0pt;">
					<p style="margin:0pt;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:41.08%;padding:0pt;">
					<p style="margin:0pt;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:55.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.36%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:41.08%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">/s/ Brian M. Hahn</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:58.92%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Date:&nbsp; November 28, 2018</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:41.08%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Brian M. Hahn</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:58.92%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:41.08%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Chief Financial Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--HTML document created with Merrill Bridge  8.2.0.61-->
<!--Created on: 11/28/2018 2:00:21 PM-->
<html>
	<head>
		<title>
			glyc_Ex99_1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt 0pt 12pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;">Exhibit 99.1</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;"><img src="ex-99d1g001.jpg" style="width: 3.76in; height: 0.82in" alt="Picture 1"></font>
		</p>
		<p style="margin:0pt;line-height:100%;border-bottom:1pt none #D9D9D9 ;text-align:center;font-family:Courier New;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 41.75pt;line-height:100%;text-indent:30.25pt;border-top:1pt none #D9D9D9 ;text-align:center;font-family:Courier New;font-weight:bold;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">SCOTT JACKSON, VETERAN BIOPHARMACEUTICAL EXECUTIVE, JOINS GLYCOMIMETICS BOARD OF DIRECTORS</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:150%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:150%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="text-transform:uppercase;display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">ROCKVILLE, MD, November 28, 2018 </font><font style="text-transform:uppercase;display:inline;font-family:Calibri;font-size:11pt;">&#x2013; &nbsp;</font><font style="display:inline;font-family:Calibri;font-size:11pt;">GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that it has appointed Scott Jackson, former Chief Executive Officer of&nbsp;Celator Pharmaceuticals, Inc., to its Board of Directors.&nbsp;Mr. Jackson&nbsp;served as Celator&#x2019;s CEO and as a member of its Board of Directors from&nbsp;April 2008&nbsp;until&nbsp;July 2016, when the company was acquired by Jazz Pharmaceuticals plc.&nbsp;</font>
		</p>
		<p style="margin:5pt 0pt;line-height:150%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">"As uproleselan advances in late-stage clinical trials in acute myeloid leukemia (AML), Scott&#x2019;s experience leading Celator through the successful development of Vyxeos&#xAE; for treatment of newly diagnosed AML patients will be invaluable to GlycoMimetics,&#x201D; said Rachel King,&nbsp;GlycoMimetics&#x2019;&nbsp;Chief Executive Officer.&nbsp;&#x201C;His deep operational experience, including in sales, marketing and commercialization, is directly relevant as we look forward to potentially commercializing this novel drug candidate.&#x201D;</font>
		</p>
		<p style="margin:5pt 0pt;background-color: #FFFFFF;line-height:150%;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Mr. Jackson&nbsp;has more than 25 years of experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly &amp; Co., SmithKline Beecham,&nbsp;ImClone Systems Inc.,&nbsp;Centocor Inc., a division of Johnson &amp; Johnson, Eximias Pharmaceutical and&nbsp;YM BioSciences.&nbsp;He holds a B.S. in pharmacy from the&nbsp;Philadelphia College of Pharmacy&nbsp;and Science and an M.B.A. from the&nbsp;University of Notre Dame.&nbsp;Mr. Jackson presently serves on the Board of Directors of MacroGenics, Inc. and the Board of Trustees of the Eastern Pennsylvania Chapter of&nbsp;The Leukemia&nbsp;and Lymphoma Society.</font>
		</p>
		<p style="margin:5pt 0pt;background-color: #FFFFFF;line-height:150%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&#x201C;I am excited to join the GlycoMimetics Board at a time when the company is making tremendous strides in the development of glycomimetic compounds, such as uproleselan for AML,&#x201D; said Mr. Jackson.&nbsp;&nbsp;&#x201C;AML is an area of high unmet medical need and uproleselan, if approved, could potentially make a significant impact on the treatment of patients with AML. I look forward to working with the Board and leadership team to advance this important drug candidate and to leverage the potential of the company&#x2019;s broad pipeline.&#x201D;</font>
		</p>
		<p style="margin:5pt 0pt;background-color: #FFFFFF;line-height:150%;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:5pt 0pt;background-color: #FFFFFF;line-height:150%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">About GlycoMimetics, Inc.&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt;line-height:150%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">GlycoMimetics&nbsp;is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.&nbsp;&nbsp;GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer.&nbsp; GlycoMimetics'&nbsp;wholly owned drug candidate, u</font><font style="display:inline;font-family:Calibri;font-size:11pt;background-color: #FFFFFF;">proleselan</font><font style="display:inline;font-family:Calibri;font-size:11pt;">, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is currently being evaluated in a company-sponsored Phase 3 trial in relapsed/refractory AML.&nbsp;The U.S. Food and Drug Administration granted uproleselan breakthrough therapy designation for&nbsp;the treatment of adult AM) patients with relapsed/refractory disease. GlycoMimetics&nbsp;has also completed a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist.&nbsp;GlycoMimetics&nbsp;is located in&nbsp;Rockville, MD&nbsp;in the&nbsp;BioHealth Capital Region. Learn more at&nbsp;</font><font style="font-family:Calibri;font-size:11pt;border-bottom-style:solid;border-bottom-width:1pt;height:100%;text-indent:0pt;">www.glycomimetics.com</font><font style="display:inline;font-family:Calibri;font-size:11pt;">.</font>
		</p>
		<p style="margin:12pt 0pt;line-height:150%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">Cautionary Note Regarding Forward-Looking Statements</font>
		</p>
		<p style="margin:12pt 0pt;line-height:150%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">This press release contains forward-looking statements, including statements regarding the clinical development and potential utility of the company&#x2019;s drug candidates. Actual results may differ materially from those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the company&#x2019;s quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on November 2, 2018, and other filings GlycoMimetics makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.</font>
		</p>
		<p style="margin:12pt 0pt;line-height:150%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt;line-height:150%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;"># # #</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Source: GlycoMimetics</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">Investor Contact:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Shari Annes</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Phone: 650-888-0902</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Email: sannes@annesassociates.com</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">Media Contact:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Jamie Lacey-Moreira</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Phone: 410-299-3310</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Email: jamielacey@presscommpr.com</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex-99d1g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d1g001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !     %$2
M  0    !             8:@  "QC__; $, " 8&!P8%" <'!PD)" H,% T,
M"PL,&1(3#Q0=&A\>'1H<'" D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T
M,O_; $,!"0D)# L,& T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_  !$( $X!:0,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M)Y_B'P'?6UF.7N+6<3;!ZD 8'XD5V^@>(M+\3Z8NH:3=+/ 3ANS(W]UAU!H
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M$/AVQUBWP(KJ$2$9^X>C*3[$$?A7$_!4!O!5Z" 0=3G!!^BUQVI:E?\ @?\
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MEM>?&LGLS_\ H-'B_P#UUK_NM_2G%1YXPY5JA2<^253F>C([F\U];<:@S>5
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M9(E\L,3][! !;OPH'H37H7A#X8Z!X1"3Q0_;-1')O+@ L#_LCHOX<^]=I10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
E110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
